MiMedx Group/$MDXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Ticker
$MDXG
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
837
ISIN
US6024961012
Website
MiMedx Group Metrics
BasicAdvanced
$871M
21.73
$0.27
1.74
-
Price and volume
Market cap
$871M
Beta
1.74
52-week high
$9.71
52-week low
$5.47
Average daily volume
657K
Financial strength
Current ratio
4.695
Quick ratio
3.959
Long term debt to equity
8.646
Total debt to equity
9.201
Dividend payout ratio (TTM)
0.42%
Interest coverage (TTM)
15.77%
Profitability
EBITDA (TTM)
62.809
Gross margin (TTM)
81.94%
Net profit margin (TTM)
11.40%
Operating margin (TTM)
15.41%
Effective tax rate (TTM)
26.67%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
13.80%
Return on equity (TTM)
22.29%
Valuation
Price to earnings (TTM)
21.734
Price to revenue (TTM)
2.465
Price to book
4.29
Price to tangible book (TTM)
5.06
Price to free cash flow (TTM)
13.449
Free cash flow yield (TTM)
7.44%
Free cash flow per share (TTM)
43.87%
Growth
Revenue change (TTM)
5.34%
Earnings per share change (TTM)
-38.83%
3-year revenue growth (CAGR)
11.02%
10-year revenue growth (CAGR)
9.71%
3-year earnings per share growth (CAGR)
16.61%
10-year earnings per share growth (CAGR)
10.77%
What the Analysts think about MiMedx Group
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
Bulls say / Bears say
MiMedx reported Q4 2024 earnings of $0.07 per share, meeting estimates and reflecting a 75% increase from the previous year's $0.04 per share, indicating strong financial performance. (nasdaq.com)
Institutional investors like Wellington Management Group LLP increased their stake in MiMedx by 22.8% during Q4 2024, signaling confidence in the company's future prospects. (marketbeat.com)
Analysts have assigned MiMedx an average 'Buy' rating with a consensus target price of $12.00, suggesting potential upside from current levels. (defenseworld.net)
MiMedx's stock reached a 52-week low of $5.56 in October 2024, reflecting significant market challenges and investor concerns. (investing.com)
The company faces competitive and regulatory hurdles, including an ongoing FDA matter with AXIOFILL, which could impact future growth. (investing.com)
Insider selling activity, such as the CAO selling 54,596 shares in March 2025, may indicate potential concerns about the company's near-term prospects. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MiMedx Group Financial Performance
Revenues and expenses
MiMedx Group Earnings Performance
Company profitability
MiMedx Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiMedx Group stock?
MiMedx Group (MDXG) has a market cap of $871M as of June 20, 2025.
What is the P/E ratio for MiMedx Group stock?
The price to earnings (P/E) ratio for MiMedx Group (MDXG) stock is 21.73 as of June 20, 2025.
Does MiMedx Group stock pay dividends?
No, MiMedx Group (MDXG) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next MiMedx Group dividend payment date?
MiMedx Group (MDXG) stock does not pay dividends to its shareholders.
What is the beta indicator for MiMedx Group?
MiMedx Group (MDXG) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.